Skip to main content
OpenTrials
Completed

NCT Number: NCT04602819

Photoaging Reversing After Picosecond Laser With DLA Assessed by Cellular Resolution OCT in Asian Patient With Melasma

Background Melasma is a commonly acquired hypermelanosis that affects facial sun exposed areas, most commonly in Asians and other darker skin type females. Recent evidence has demonstrated melasma to be a photoaging disorder. The histological findings of melasma are similar to photoaging and include solar elastosis, increased mast cells and sebaceous glands, as well as increased vascularization. Pendulous active melanocytes with weakened basal membranes, and changes in nuclear morphology and chromatin texture of adjacent basal keratinocytes also seemed to be a characteristic feature of melasma.

Objectives:

To compare the difference of photoaging features of melasma skin and normal skin by optical coherence tomography (ApolloVue® S100 Image System, a 510(K) class II medical device) and reversal of photoaing features by 755nm picosecond alexandrite laser with diffractive lens.

Methodology:

We enroll 20 adults with facial melasma. The patients received 755nm picosecond alexandrite laser with diffractive lens array over whole face at W0, W4, and W8. Evaluation with VISIA, optical coherence tomography, Cutometer MPA580 at W4, W8, W12. All the patients will be instructed with use of moisturizer, gentle cleaning, and sunscreen use.

Anticipated results and applications:

This study expects to

1. understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography and other noninvasive methods. 2. Set evidence based guidance for melasma treatment and set the protocol or clinical path.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

China Medical University Hospital

Taichung, 404332, Taiwan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing to sign a written inform consent form
  • Adults over the age of 20.
  • Patients with melasma on their faces.

Exclusion criteria

  • have received any cosmetic treatments, e.g. laser, pulsed light, and chemical peels within six months before participating the trial.
  • Have taken oral contraceptives or received hormone therapy within one year before participating the trial.
  • Has other pigmented diseases or inflammatory diseases on face.
  • Are pregnant or breastfeeding.
  • Has conditions with poor wound healing, keloids or photosensitivity.

Treatment and study plan

PicoSure 755nm picosecond alexandrite laser with diffractive lens

Device

Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography and other noninvasive methods.

ApolloVue® S100 Image System

Device

Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography.

Other names: 510(K) Number: K201552 (class II)

Cutometer® dual MPA 580

Device

Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the Cutometer® dual MPA 580.

VISIA®

Device

Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the VISIA®.

Primary outcomes

  1. Clinical improvement of melasma

    Time frame: 4 weeks

    Clinical improvement of melasma after picosecond laser treatment will be assessed by both physician and patient at week 0, week 4, week 8, and week 12.

  2. Improvement of MASI score

    Time frame: 4 weeks

    Improvement of melasma after picosecond laser treatment will be assessed using MASI score that will be calculated according to the image taken by VISIA at week 0, week 4, week 8, and week 12.

  3. Improvement of hydration, TEWL, viscoelasticity, or melanin and erythema index

    Time frame: 4 weeks

    Improvement of melasma after picosecond laser treatment will be assessed using Cutometer® MPA 580 at week 0, week 4, week 8, and week 12.

  4. Number of subjects with clear tissue characteristics of melasma and/or normal skin in tomograms

    Time frame: 4 weeks

    Number of subjects with clear tissue characteristics of tomograms will be compared to that with unclear tissue characteristics to identify the effect of the OCT on scanning melasma at study completion.

Secondary outcomes

  1. Number of subjects with the distinction between melasma and normal skin in tomograms

    Time frame: 1 year

    Number of subjects with the distinction between melasma and normal skin in tomograms will be compared to that with no distinction to verify the specific diseases that can be distinguished from others by the OCT at study completion.

Sponsors and collaborators

Lead sponsor

China Medical University Hospital

Other

Collaborators

  • Apollo Medical Optics, Ltd

Registry information

Official study title

Photoaging Reversing After Picosecond Laser With Diffractive Focus Lens Assessed by Cellular Resolution Optical Coherent Tomography in Asian Patient With Melasma

Important dates

Study start
2021
Primary completion
2021
Study completion
2022
First posted
Oct 26, 2020
Registry last updated
Jul 20, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.